[1]阚 通,章 伟,张 敏,等.射频消融犬心室流出道间隔初步实验研究[J].介入放射学杂志,2017,(02):153-156.
 KAN Tong,ZHANG Wei,ZHANG Min,et al.Radiofrequency ablation of ventricular outflow tract septum: a preliminary study in experimental canine[J].journal interventional radiology,2017,(02):153-156.
点击复制

射频消融犬心室流出道间隔初步实验研究 ()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2017年02期
页码:
153-156
栏目:
实验研究
出版日期:
2017-02-25

文章信息/Info

Title:
Radiofrequency ablation of ventricular outflow tract septum: a preliminary study in experimental canine
作者:
阚 通 章 伟 张 敏 张 建 储国俊 秦永文
Author(s):
KAN Tong ZHANG Wei ZHANG Min ZHANG Jian CHU Guojun QIN Yongwen
Department of Cardiology, Affiliated Changhai Hospital, Second Military Medical University, Shanghai 200433, China
关键词:
【关键词】 肥厚型心肌病 室间隔 心室流出道梗阻 经导管射频消融
文献标志码:
A
摘要:
【摘要】 目的 初步探讨射频消融犬心室流出道间隔对左心室结构与功能的影响。方法 以健康实验犬为模型,射频消融心室流出道间隔处肌肉。术前经胸超声检测左心室流出道宽度、收缩期室间隔厚度和射血分数等指标,消融成功后即刻检测超声指标,术后1、3个月分别复查存活犬超声指标,作组织病理学检查。结果 10只实验犬中9只消融成功,1只术中发生室颤死亡;1只消融成功但麻醉过深,出现呼吸抑制死亡。手术即刻成功率为80%,8只术后存活至预定随访时间点。与术前相比,存活犬术后即刻、术后1个月、术后3个月左心室流出道宽度、收缩期室间隔厚度差异均有统计学意义(P<0.05),射血分数差异均无统计学意义(P>0.05);组织病理学检查可见明显改变;心电图、血压未见明显变化。结论 初步验证射频消融实验犬心室流出道间隔心肌具有一定的安全性和有效性,为进一步动物实验和临床试验提供了有用参数和实验依据。

参考文献/References:

[1] Lopes LR, Zekavati A, Syrris P, et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequen-cing[J]. J Med Genet, 2013, 50: 228-239.
[2] McKenna WJ, Deanfield JE. Hypertrophic cardiomyopathy: an important cause of sudden death[J]. Arch Dis Child, 1984, 59: 971-975.
[3] McKenna WJ, Krikler DM, Goodwin JF. Arrhythmias in dilated and hypertrophic cardiomyopathy[J]. Med Clin North Am, 1984, 68: 983-1000.
[4] Maron BJ, Maron MS. Hypertrophic cardiomyopathy[J]. Lancet,2013, 381: 242-55.
[5] 肥厚型梗阻性心肌病室间隔心肌消融术中国专家共识组. 肥厚型梗阻性心肌病室间隔心肌消融术中国专家共识[J]. 中国医药科学. 2012, 10: 3-4.
[6] Lawrenz T, Borchert B, Leuner C, et al. Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyo-pathy: acute results and 6 months’ follow-up in 19 patients[J]. J Am Coll Cardiol, 2011, 57: 572-576.
[7] Sreeram N, Emmel M, De Giovanni JV. Percutaneous radiofrequency septal reduction for hypertrophic obstructive cardiomyopathy in children[J]. J Am Coll Cardiol, 2011, 58: 2501-2510.
[8] 石蕴琦, 李占全. 梗阻性肥厚型心肌病介入治疗与手术治疗的比较[J]. 中国介入心脏病学杂志, 2015, 23: 291-293.
[9] Towbin JA. Hypertrophic cardiomyopathy[J]. Pacing Clin Electro-physiol, 2009, 32(Suppl 2): S23-S31.
[10] Gersh BJ, Maron BJ, Bonow RO. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy (vol 42, pg 1687, 2003)[J]. J Am Coll Cardiol, 2012, 59: 434.
[11] Maron BJ. Hypertrophic cardiomyopathy: a systematic review[J]. JAMA, 2002, 287: 1308-1320.
[12] Kuhn H, Seggewiss H, Gietzen FH, et al. Catheter-based therapy for hypertrophic obstructive cardiomyopathy. First in-hospital outcome analysis of the German TASH Registry[J]. Z Kardiol, 2004, 93: 23-31.
[13] Zeng Z, Wang F, Dou X, et al. Comparison of percutaneous transluminal septal myocardial ablation versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy: a meta analysis[J]. Int J Cardiol, 2006, 112: 80-84.
[14] Kuhn H, Lawrenz T, Lieder F, et al. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy(TASH): a 10 year experience[J]. Clin Res Cardiol, 2008, 97: 234-243.
[15] Maron BJ. Hypertrophic cardiomyopathy in childhood[J]. Pediatr Clin North Am, 2004, 51: 1305-1346.
[16] Hsieh TC, Patel K. Echocardiography-guided alcohol septal ablation for hypertrophic obstructive cardiomyopathy[J]. Anesth Analg, 2011, 113: 44-46.
[17] Fifer MA, Vlahakes GJ. Management of symptoms in hypertrophic cardiomyopathy[J]. Circulation, 2008, 117: 429-439.
[18] Yamane T, Jais P, Shah DC, et al. Efficacy and safety of an irrigated-tip catheter for the ablation of accessory pathways resistant to conventional radiofrequency ablation[J]. Circulation, 2000, 102: 2565-2568.

相似文献/References:

[1]吴 弘,王启平,秦永文,等. 经皮腔内室间隔心肌消融术治疗肥厚型梗阻性心肌病的长期疗效及安全性观察[J].介入放射学杂志,2014,(02):104.
 WU Hong,WANG Qi? ping,QIN Yong? wen,et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: its long?蛳 term efficacy and safety[J].journal interventional radiology,2014,(02):104.

备注/Memo

备注/Memo:
(收稿日期:2016-09-04)
(本文编辑:边 佶)
更新日期/Last Update: 2017-02-13